Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | NAAA | Q02083 | 1/20 | 0.58 |
| ▸ | DGKA | P23743 | 1/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 2/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | PAM | P19021 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3822217 | 1.00 | HTR2C (1.00) | HTR2CNAAADGKAPRSS1PRSS2 | |
| SCHEMBL3829077 | 1.00 | HTR2C (1.00) | HTR2CNAAADGKAPRSS1PRSS2 | |
| SCHEMBL3822297 | 1.00 | HTR2C (1.00) | HTR2CNAAADGKAPRSS1PRSS2 | |
| SCHEMBL3824698 | 1.00 | HTR2C (1.00) | HTR2CNAAADGKAPRSS1PRSS2 | |
| SCHEMBL3819717 | 1.00 | HTR2C (1.00) | HTR2CNAAADGKAPRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL1613827 | 0.98 | HTR2C (0.97) | HTR2CNAAADGKAPRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL1613756 | 0.98 | HTR2C (0.97) | HTR2CNAAADGKAPRSS1PRSS2 | |
| Hexaminolevulinate SCHEMBL937621 | 0.98 | HTR2C (0.97) | HTR2CNAAADGKAPRSS1PRSS2 | |
| SCHEMBL987595 | 0.98 | HTR2C (0.96) | HTR2CNAAADGKAPRSS1PRSS2 | |
| SCHEMBL987461 | 0.93 | HTR2C (0.86) | HTR2CNAAADGKAPRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12433477-B2 | Contrast enhancement for medical imaging | STRYKER CORPORATION (US) | 2025-10-07 | — | — | US | claimed |
| EP-4602049-A1 | SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-08-20 | — | — | EP | claimed |
| EP-4587439-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-07-23 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-15 | — | — | US | claimed |
| EP-4532008-A1 | ULTRASOUND ARRAYS FOR ENHANCED TISSUE THERAPY | Alpheus Medical, Inc. (US) | 2025-04-09 | — | — | EP | claimed |
| US-12239707-B2 | Photodynamic compositions and methods of use | MT RESEARCH, LLC (US) | 2025-03-04 | — | — | US | claimed |
| WO-2025021997-A1 | NEW MAP4K1 INHIBITORS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-01-30 | — | — | WO | claimed |
| WO-2025016899-A1 | SPIROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2025-01-23 | — | — | WO | claimed |
| EP-4476221-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | Bayer Aktiengesellschaft (DE) | 2024-12-18 | — | — | EP | claimed |
| EP-2136844-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | Centre De Recherche Sur Les Biotechnologies Marine (CA) | 2009-12-30 | — | — | EP | claimed |
| US-20090280061-A1 | ESTERS OF 5-AMINOLEVULINIC ACID AS PHOTOSENSITIZING AGENTS IN PHOTOCHEMOTHERAPY | GIERSKCKY KARL E | 2009-11-12 | — | — | US | claimed |
| US-7530461-B2 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy | PHOTOCURE ASA (NO) | 2009-05-12 | — | — | US | claimed |
| WO-2008113177-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) | 2008-09-25 | — | — | WO | claimed |
| US-7335684-B2 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy | PHOTOCURE ASA (NO) | 2008-02-26 | — | — | US | claimed |
| US-7247655-B2 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy | PHOTOCURE ASA (NO) | 2007-07-24 | — | — | US | claimed |
| EP-1467706-B1 | DERMAL APPLICATION SYSTEM FOR AMINOLEVULINIC ACID-DERIVATIVES | PHOTONAMIC GMBH & CO KG (DE) | 2007-03-14 | — | — | EP | claimed |
| US-20060084701-A1 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy | GIERSKEKY KARL E | 2006-04-20 | — | — | US | claimed |
| US-20060018956-A1 | Dermal application system for aminolevulinic acid-derivatives | PHOTONAMIC GMBH & CO. KG (DE) | 2006-01-26 | — | — | US | claimed |
| US-20050031541-A1 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy | PHOTOCURE ASA (NO) | 2005-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | KRAS, NRAS, TP53 | HTR2C 4827/4885NAAA 4488/4885DGKA 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.